c‐erbB‐2 and ras expression levels in breast cancer are correlated and show a co‐operative association with unfavorable clinical outcome

Abstract

C‐erbB‐2 and ras expression was measured on tumor extracts from 132 human primary breast carcinomas, by immunoblotting analysis. Expression of the c‐erbB‐2‐encoded p 185 protein was observed in 39% of the samples and found to correlate with c‐erbB‐2 gene amplification, detected by Southern analysis in 19 of the 77 available tumor DNAs. P185 expression was linked to the absence of progesterone receptors, but it was not related to lymph‐node status or to other clinico‐pathological parameters. Levels of the ras‐encoded p2l proteins higher than in normal breast tissues were found in 71% of the samples. No significant correlation was seen between p21 level and the available clinical parameters. Conversely, there was a strong positive correlation between p2l and p185 levels. Analysis of follow‐up data revealed that p185 expression was associated with a shorter time to relapse and death. Most notably, the contemporaneous expression of p 185 and of high p21 levels was more effective than p185 expression alone in identifying cases with poor prognosis. The prognostic value of p185/p21 co‐expression was particularly significant in progesterone‐receptor‐positive tumors. Our data suggest that c‐erbB‐2 and ras may act synergistically to endow breast‐tumor cells with a highly aggressive phenotype.